Innoviva delivered a strong third-quarter performance with total revenue reaching $107.8 million, a 20% increase year-over-year. This growth was fueled by resilient royalty revenue and a 52% year-over-year increase in U.S. net product sales. The company also reported a substantial net income of $89.9 million and launched ZEVTERA® in the U.S., while announcing a $125 million share repurchase program.

Innoviva reported a net loss of $46.6 million in the first quarter of 2025, primarily due to unfavorable changes in investment values. However, the company's core royalty platform maintained strong performance, net product sales increased significantly by 59% year-over-year driven by a 52% increase in U.S. product sales, and income from operations grew by 61%.

Innoviva, Inc. delivered an exceptional Q4 2024, with total revenue reaching $91.8 million, up from $85.84 million in the prior year. The company's core royalty platform contributed $62.52 million, while Innoviva Specialty Therapeutics achieved U.S. net product sales of $24.9 million, reflecting a 47% year-over-year growth. Net income for the quarter was $20.332 million, or $0.32 per basic share.

Innoviva reported strong Q3 2024 financial results, driven by solid performance from core GSK royalty assets and accelerating sales from IST commercial products. The company is on track to submit an NDA for zoliflodacin to the U.S. FDA in early 2025.

Innoviva reported a robust second quarter, demonstrating successful transformation with strong performance across the core GSK royalties portfolio and accelerating growth from commercial products GIAPREZA, XACDURO, and XERAVA. The company remains focused on enhancing shareholder value through capital allocation and operational excellence.

Innoviva reported a strong first quarter with a focus on its core GSK royalties portfolio and revenue growth across its commercial products. The company is focused on driving shareholder value through cost discipline, strategic investments, and share buybacks.

Innoviva reported strong cash flow from its core royalty portfolio and significant pipeline and commercial progress in its therapeutics platform. The company ended the year with over $275 million in cash and account receivables, while returning capital with share repurchases of over $75 million and paying down outstanding debt of nearly $100 million.

Innoviva reported a net income of $82.0 million for Q3 2023, with gross royalty revenue from GSK at $57.0 million and net product sales and license revenue at $13.7 million. The company launched XACDURO® and announced positive topline Phase 3 zoliflodacin data.

Innoviva reported strong Q2 2023 financial results with significant revenues from its royalty portfolio and internal product portfolio. The company received FDA approval for XACDURO® and repurchased $9.2 million of common stock.

Innoviva reported strong Q1 2023 results with significant revenue from royalties and product sales. Net income increased to $34.9 million, and the company repurchased $40.3 million in common stock and paid off $96.2 million in convertible notes.

Innoviva reported solid results in its diversified core royalty business, with RELVAR®/BREO® ELLIPTA® global net sales decreasing due to unfavorable adjustments in the U.S., offset by stable volume trends. GIAPREZA® and XERAVA® had their strongest quarter ever, and the company is advancing its strategy of building a best-in-class hospital and infectious disease business.

Innoviva reported strong revenue from its diversified core royalty business despite challenging market conditions. The acquisitions of Entasis and La Jolla have given the company a strong footprint in the hospital and infectious disease space.

Innoviva's core royalty business continued to deliver strong revenues, and the company meaningfully advanced its strategy via key strategic and opportunistic transactions, including the acquisition of Entasis and the announced acquisition of La Jolla.

Innoviva reported its Q1 2022 financial results, highlighting a 5% year-over-year growth in royalty revenues. The company saw growth in TRELEGY® ELLIPTA® global net sales, offset by a decrease in ANORO® ELLIPTA® global net sales. Innoviva also consolidated Entasis financials and refinanced debt, which impacted reported income.

Innoviva reported an 18% year-over-year growth in royalty revenues for the fourth quarter, driven by strong performance in its core royalty business and strategic investments.

Innoviva reported strong royalty revenue growth of 10% year-over-year. Net income per share exceeded $1, supported by a recently completed equity repurchase.

Innoviva reported a 44% year-over-year growth in royalty revenues, driven by the strength and resilience of its respiratory assets partnered with Glaxo Group Limited (GSK). The company deployed over $400 million in strategic investments and executed on its strategy of creating shareholder value through operational excellence.

Innoviva reported its Q1 2021 financial results, highlighting an 8% year-over-year growth in royalty revenues, which was positively impacted by non-recurring items such as prior-period adjustments and favorable foreign exchange rates. The company strategically deployed capital in healthcare companies and resolved its arbitration with Theravance BioPharma.

Innoviva reported strong Q4 2020 results with global net sales increases for RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA® by 5%, 10%, and 42% respectively, compared to the same quarter of 2019. The company successfully deployed nearly $400 million of capital across promising assets.

Innoviva reported an increase in RELVAR®/BREO® ELLIPTA® global net sales by 38% compared to the third quarter of 2019 and TRELEGY® ELLIPTA® global net sales were $251.9 million, compared to $172.8 million during the comparable period a year ago.

Innoviva reported its Q2 2020 financial results, noting a decrease in RELVAR®/BREO® ELLIPTA® global net sales by 3% year-over-year, while ANORO® ELLIPTA® global net sales increased by 5%. TRELEGY® ELLIPTA® global net sales were $240.5 million compared to $151.4 million in the same period last year.

Innoviva reported an increase in global net sales for RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA® in the first quarter of 2020.

Innoviva's Q4 2019 results showed a decrease in RELVAR®/BREO® ELLIPTA® global net sales by 18% and a 2% decline in ANORO® ELLIPTA® global net sales. However, TRELEGY® ELLIPTA® global net sales were $221.4 million. Despite challenges, the company's full-year income from operations rose, cash resources increased, and debt levels declined.